Concerns Over Genetic Mutations in Sperm Donors

Sperm donors who contributed to nearly 200 births across Europe were found to carry genetic mutations linked to cancer. This has raised serious concerns about hidden risks connected to various childhood illnesses and even premature death.

An investigation, primarily conducted by the BBC alongside other public media outlets, highlighted that these donations were made to the European Sperm Bank (ESB) in Denmark, subsequently used in 67 fertility clinics across 14 countries over a span of 17 years.

The unidentified donor in question began providing samples as a student in 2005, according to the findings.

The initial medical screening did not indicate issues, but the donor was unknowingly carrying a harmful mutation affecting the TP53 gene. This gene plays a crucial role in preventing cancer by repairing DNA damage and initiating the death of cancerous cells.

Research has shown that mutations in this gene can hinder these protective functions, leading to uncontrolled cell growth and tumor formation.

Reports indicate that up to 20% of this donor’s sperm contained the mutation, meaning that offspring conceived through it would carry the genetic issue in every cell of their bodies.

As a result, children born from this sperm face a staggering 90% likelihood of encountering some type of cancer in their lifetime, including breast cancer, bone cancer, brain cancer, and leukemia. This condition is referred to as Li-Fraumeni syndrome.

During a recent meeting of the European Society of Human Genetics (ESHG) in Milan, doctors voiced these troubling findings. Expert Edwig Kasper shared the case of a sperm donor with the detrimental mutation.

“This represents an extraordinary epidemic of a genetic disease. It’s not common for a single man across Europe to father 75 children,” said Kasper.

At that time, it was confirmed that 23 children had the mutation, with 10 already diagnosed with cancer. Although 197 children were born from this sperm, the actual number might be much higher since not all data has been documented.

Kasper advocated for restrictions on the number of births per donor in Europe. “While I’m not suggesting we sequence every sperm donor’s entire genome, the prevalence of this genetic disease is alarming,” she said.

Furthermore, she emphasized the importance of genetic counseling for children conceived from this donor’s sperm. “Some have already developed multiple cancers, and tragically, some are dying young,” Kasper explained in discussions with investigators.

According to the European Society of Human Reproduction and Embryology (ESHRE), there currently are no universal laws capping how many times a donor’s sperm can be used or how many children one donor can have. However, individual countries may have their own regulations, and ESHRE is advocating for a potential international limit of 50 families per donor.

Dr. Mark Siegel, a senior medical analyst, remarked on the implications of these developments. “This distressing story underscores the urgent need for modern genetic screenings for all donors,” he stated. He also noted that knowing the donor might provide a beneficial context.

“Genetic testing related to cancers has significantly improved and should be standard practice in sperm donations,” Siegel added, advocating for the use of AI to enhance these processes.

The European Sperm Bank has expressed deep sympathies for the affected families, acknowledging the significant impact of the rare TP53 mutation on numerous lives.

“We are profoundly affected by this situation and extend our heartfelt condolences to all who have been impacted,” the ESB stated.

In a further clarification, the ESB mentioned this specific mutation appears in only a small portion of the donor’s sperm and is not present elsewhere in the body. After the confirmation of the mutation in 2023, the donor was blocked from future donations, and the relevant clinics were informed.

“Both the donor and their family are not ill, and such mutations typically wouldn’t be detected through standard genetic screenings,” the agency noted.

Clinics hold the responsibility to inform patients as they may not have direct knowledge of the donors, making physicians the most suitable source for specific advice.

The American Society for Reproductive Medicine (ASRM) has advised that all potential donors undergo proper genetic evaluations, ensuring they are healthy and devoid of any genetic disease history. Concerns have been raised for parents to reach out to their treatment clinics or fertility authorities in their respective countries for guidance.